The non-alcoholic steatohepatitis (NASH) market is projected to reach US$ 24,266.81 million by 2028 from US$ 1,631.92 million in 2021; it is expected to register a CAGR of 47.1% from 2021 to 2028.
In nonalcoholic fatty liver disease (NAFLD), fat builds up in the liver. Non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) are types of NAFLD. When the fat buildup causes inflammation and damage, it leads to the development of NASH, which can lead to scarring of the liver. The scarring of the liver is a potentially life-threatening condition called cirrhosis.
The report offers insights and in-depth analysis of the non-alcoholic steatohepatitis (NASH) market emphasizing various parameters such as market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, it includes the impact of the COVID-19 pandemic on the market across all the regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. In North America, the US was profoundly affected by the COVID-19 pandemic. Liver injury in the form of increased transaminases and hyperbilirubinemia among COVID-19 patients can be attributed to a couple of factors, including pre-existing liver disease. The comorbidity of nonalcoholic fatty liver disease (NAFLD) and NASH in these patients makes them prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it is far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and COVID severity. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients.
The impact of COVID-19 on comorbid patient populations, including people with diabetes, obesity, fatty liver disease, and NASH, has triggered the need of providing optimal care to patients. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. Research revolving around combating NAFLD and NASH indicates that the anticipated relationship with weight problems is stark. Therefore, a high incidence of NASH demands advanced diagnostics and treatments, which boosts research and development in the market. Thus, the COVID-19 crisis has fueled the non-alcoholic steatohepatitis (NASH) market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Non-Alcoholic Steatohepatitis (NASH) Market: Strategic Insights
Market Size Value in US$ 1,631.92 million in 2021 Market Size Value by US$ 24,266.81 million by 2028 Growth rate CAGR of 47.1% from 2021 to 2028. Forecast Period 2021- 2028 Base Year 2021
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Non-Alcoholic Steatohepatitis (NASH) Market: Strategic Insights
| Market Size Value in | US$ 1,631.92 million in 2021 |
| Market Size Value by | US$ 24,266.81 million by 2028 |
| Growth rate | CAGR of 47.1% from 2021 to 2028. |
| Forecast Period | 2021- 2028 |
| Base Year | 2021 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Lucrative Regions for Non-Alcoholic Steatohepatitis (NASH) Market
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Market Insights
Increasing Initiatives for Boosting Awareness of NASH Drive Market Growth
NASH is an under-recognized condition. For a structured referral pathway and early detection, building greater awareness of this disease among the general public and primary care physicians (PCPs) is essential. By establishing a clear patient pathway for referrals and patient awareness campaigns, more individuals can be identified and sent to specialists for further evaluation. To raise awareness of NASH, the NASH Education Program launched the public education campaign on June 12, 2018, observed as the "International NASH Day," to raise awareness about the NAFLD and its more advanced form, NASH, which affects over ~115 million people.
NASH 24X7, a digital platform aimed at raising exposure and awareness regarding the NASH epidemic, took a few steps on the International NASH Day 2019 through HCP support, patient awareness, and press/TV release programs. To raise awareness on this day, NASH Crusaders of NASH 24X7 joined with top healthcare providers (HCPs), especially gastroenterologists and hepatologists, across India to hold many small and large-scale awareness & education workshops on liver health, highlighting the necessity of a healthy lifestyle in preventing NAFLD/NASH.
On the International NASH Day 2020, the American Liver Foundation joined a global community to raise awareness about NASH with support from the Allergan Foundation. American Liver Foundation (ALF) is now piloting a NASH Text Messaging Program, wherein people can sign up to receive weekly 3 messages for 10 weeks. Messages consist of hyperlinks to NASH resources, relevant facts, interactive quizzes, and sensible pointers for daily self-management. The ALF will open this system to the general public when the pilot is finished and evaluated. It collaborated with the Global Liver Institute (GLI) on the International NASH Day, and shared a few social media posts linked to GLI posts and the International NASH day page.
Thus, rising initiatives for the propelling the awareness regarding NASH are driving the non-alcoholic steatohepatitis (NASH) market.
Product-Based Insights
Based on product, the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR of 73.3% during the forecast period.
Organ Preservation Solutions Market, by Product – 2020 and 2028
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Application-Based Insights
Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR of 47.3% during the forecast period.
Sales Channel-Based Insights
Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacy segment held the largest share of the market. Moreover, the retail pharmacies segment is expected to report the highest CAGR of 47.2% during 2021–2028.
The non-alcoholic steatohepatitis (NASH) market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.
By
Geography
Based on geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Company Profiles
- Genfit SA
- One Way Liver, S.L.
- BioPredictive S.A.S.
- Cadila Pharmaceuticals Ltd.
- Prometheus Laboratories
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product, Application, and Sales Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are types of NAFLD. Non-alcoholic steatohepatitis (NASH) is an advanced form of non-alcoholic fatty liver disease (NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis.
Key factors that are driving the growth of this market are the rising prevalence of NASH and increasing initiatives for the awareness of NASH. Additionally, the growing clinical trials involving combination studies of drugs is likely to emerge as a significant future trend in the market during the forecast period.
The CAGR value of the non-alcoholic steatohepatitis (NASH) market during the forecasted period of 2021–2028 is 47.1%.
The product segment of the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market, by product. The selonsertib & cenicriviroc segment of the non-alcoholic steatohepatitis (NASH) market is expected to witness growth in its demand at the fastest CAGR of 73.3% from 2024 to 2028.
The treatment segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 84.90% in 2021.
The retail pharmacy segment dominated the global non-alcoholic steatohepatitis (NASH) market and accounted for the largest market share of 61.39% in 2021.
The non-alcoholic steatohepatitis (NASH) market majorly consists of players such as Genfit SA; One Way Liver, S.L.; BioPredictive S.A.S.; Cadila Pharmaceuticals Ltd.; Prometheus Laboratories; Siemens Healthineers AG; Intercept Pharmaceuticals, Inc.; Novartis AG; Galmed Pharmaceuticals; and Laboratory Corporation of America Holdings amongst others.
Intercept Pharmaceuticals, Inc and Genfit SA are the top two companies that hold huge market shares in the non-alcoholic steatohepatitis (NASH) market.
North America held the largest market share for non-alcoholic steatohepatitis in 2021. The United States held the largest market in North America for non-alcoholic steatohepatitis, and the market is expected to grow due to increasing adoption of technological advancements and rising emphasis on improving treatment outcomes are projected to accelerate the growth of the non-alcoholic steatohepatitis market.
The presence of nonalcoholic fatty liver disease (NAFLD) and NASH in patients with COVID-19 is likely to cause them to be prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it's far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and the severity of COVID-19. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients. Additionally, there seems to be an increased likelihood of liver injury in NAFLD patients with COVID-19.
NASH had the strongest association with COVID-19 of all comorbid metabolic conditions, including hypertension and obesity. As the world keeps confronting the novel coronavirus pandemic, the impact of COVID-19 on specific patient populations, which includes people with diabetes, obesity, fatty liver disease, and NASH, has proven the need of providing actionable recommendations to clinicians and patients to offer optimal care and avoid needless deaths. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. As the push to combat NAFLD and NASH continues, research indicates that the anticipated relationship with weight problems is stark. Individuals with signs and symptoms of underlying fatty liver disease and NASH are at higher risk and infectious for longer for COVID-19. Therefore, COVID-19 is affected positively on the growth of the market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Non-Alcoholic Steatohepatitis Market – By Product
1.3.2 Global Non-Alcoholic Steatohepatitis Market – By Application
1.3.3 Global Non-Alcoholic Steatohepatitis Market – By Sales Channel
1.3.4 Global Non-Alcoholic Steatohepatitis Market – By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Non-Alcoholic Steatohepatitis Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of NASH
5.1.2 Increasing Initiatives for the Awareness of NASH
5.2 Market Restraints
5.2.1 Lack of Established Guidelines in the Diagnosis and Management of NASH
5.2.2 Withdrawal of Drugs from Seeking Marketing Authorization for NASH
5.3 Market Opportunities
5.3.1 Growing Opportunities in Developing Nations
5.3.2 High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity
5.4 Future Trends
5.4.1 Growing Clinical Trials Involving Combination Studies of Drugs
5.5 Impact Analysis
6. Non-alcoholic steatohepatitis (NASH) Market– Global Analysis
6.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
6.1.1 Global Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis
6.1.2 Global Non-Alcoholic Steatohepatitis Market – Market Potential Analysis, By Region
6.2 Market Positioning Analysis of Key Players in Non-Alcoholic Steatohepatitis Market
6.2.1 Company Analysis
6.2.2 Growth Strategy Analysis
6.2.3 Performance of Key Players
6.2.3.1 Intercept Pharmaceuticals, Inc.
6.2.3.2 Galmed Pharmaceuticals, Inc.
7. Global Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product
7.1 Overview
7.2 Product Market Revenue and Forecast Analysis (US$ Mn)
7.3 Vitamin E and Pioglitazone
7.3.1 Overview
7.3.2 Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)
7.4 Ocaliva
7.4.1 Overview
7.4.2 Ocaliva Revenue and Forecast to 2028 (US$ Mn)
7.5 Elafibranor
7.5.1 Overview
7.5.2 Elafibranor Revenue and Forecast to 2028 (US$ Mn)
7.6 Selonsertib & Cenicriviroc
7.6.1 Overview
7.6.2 Selonsertib Revenue and Forecast to 2028 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Revenue and Forecast to 2028 (US$ Mn)
8. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application
8.1 Overview
8.2 Application Market Revenue and Forecast Analysis (US$ Mn)
8.3 Treatment
8.3.1 Overview
8.3.2 Treatment Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diagnosis
8.4.1 Overview
8.4.2 Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)
9. Global Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel
9.1 Overview
9.2 Sales Channel Market Revenue and Forecast Analysis (US$ Mn)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
9.5 Online Provider
9.5.1 Overview
9.5.2 Online Provider Market Revenue and Forecast to 2028 (US$ Mn)
10. Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Geographical Analysis
10.1 North America: Non-Alcoholic Steatohepatitis Market
10.1.1 Overview
10.1.2 North America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3 North America: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.4 North America: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)
10.1.5 North America: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)
10.1.6 North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)
10.1.6.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.1.1 US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.1.2 US: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.6.1.3 US: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)
10.1.6.1.4 US: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)
10.1.6.2 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.2.1 Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.2.2 Canada: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.6.2.3 Canada: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)
10.1.6.2.4 Canada: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)
10.1.6.3 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.3.1 Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.3.2 Mexico: Non-Alcoholic Steatohepatitis Market, by Product, 2019–2028 (US$ Million)
10.1.6.3.3 Mexico: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (US$ Million)
10.1.6.3.4 Mexico: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (US$ Million)
10.2 Europe: Non-alcoholic steatohepatitis (NASH) Market
10.2.1 Overview
10.2.2 Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.3 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.4 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.5 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.2.6 Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)
10.2.6.1 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.1 Overview
10.2.6.1.2 Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.3 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.4 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.6.1.5 Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.2.6.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.1 Overview
10.2.6.2.2 France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.3 France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.4 France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.6.2.5 France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.2.6.3 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.1 Overview
10.2.6.3.2 UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.3 UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.4 UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.6.3.5 UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.2.6.4 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.1 Overview
10.2.6.4.2 Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.3 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.4 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.6.4.5 Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.2.6.5 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.1 Overview
10.2.6.5.2 Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.3 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.4 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.6.5.5 Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.2.6.6 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.1 Overview
10.2.6.6.2 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.3 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.4 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
10.2.6.6.5 Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecasts To 2028
10.3.1 Overview
10.3.2 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market - Revenue and Forecast to 2028 (USD Million)
10.3.3 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.4 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.5 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.3.6 Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)
10.3.6.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.1.1 China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.1.2 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.6.1.3 China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.6.1.4 China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.3.6.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.2.1 Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.2.2 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.6.2.3 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.6.2.4 Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.3.6.3 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.3.1 India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.3.2 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.6.3.3 India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.6.3.4 India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.3.6.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.4.1 Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.4.2 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.6.4.3 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.6.4.4 Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.3.6.5 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.5.1 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.5.2 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.6.5.3 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.6.5.4 South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.3.6.6 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.6.1 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
10.3.6.6.2 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product, 2019–2028 (USD Million)
10.3.6.6.3 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application, 2019–2028 (USD Million)
10.3.6.6.4 Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel, 2019–2028 (USD Million)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market
10.4.1 Overview
10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.3 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Product (US$ Million)
10.4.4 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Application (US$ Million)
10.4.5 Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)
10.4.6 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)
10.4.6.1 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.1.1 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.1.2 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
10.4.6.1.3 UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)
10.4.6.1.4 UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)
10.4.6.2 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.2.1 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.2.2 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
10.4.6.2.3 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)
10.4.6.2.4 Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)
10.4.6.3 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.3.1 South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.3.2 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
10.4.6.3.3 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)
10.4.6.3.4 South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.4.6.4 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.4.1 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
10.4.6.4.2 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
10.4.6.4.3 Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast To 2028, By Application (US$ Million)
10.4.6.4.4 Rest of Middle East & Africa: D Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
10.5 South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast To 2028
10.5.1 Overview
10.5.2 South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.3 South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.5.4 South and Central America: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)
10.5.5 South and Central America: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)
10.5.6 South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)
10.5.6.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.6.1.1 Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.6.1.2 Brazil: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.5.6.1.3 Brazil: Non-Alcoholic Steatohepatitis Market, by Application, 2019–2028 (USD Million)
10.5.6.1.4 Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)
10.5.6.2 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.6.2.1 Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.6.2.2 Argentina: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.5.6.2.3 Argentina: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)
10.5.6.2.4 Argentina: Non-Alcoholic Steatohepatitis Market, by Sales Channel, 2019–2028 (USD Million)
10.5.6.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.6.3.1 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
10.5.6.3.2 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product, 2019–2028 (USD Million)
10.5.6.3.3 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application, 2019–2028 (USD Million)
10.5.6.3.4 Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel, 2019–2028 (USD Million)
11. Impact Of COVID-19 Pandemic on Non-alcoholic steatohepatitis (NASH) Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
11.5 South and Central America: Impact Assessment of COVID-19 Pandemic
12. Non-alcoholic steatohepatitis (NASH) Market–Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Non-Alcoholic Steatohepatitis Market
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Cadila Pharmaceuticals Ltd.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Intercept Pharmaceuticals, Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Novartis AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Galmed Pharmaceuticals.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 GENFIT.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 ONE WAY LIVER, S.L
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 BioPredictive S.A.S
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Prometheus Laboratories
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Siemens Healthineers AG
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Laboratory Corporation of America Holdings
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Discontinued Drugs and Companies
Table 2. Drug, Phase, and Company
Table 3. North America Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 6. US Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 7. US Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 8. US Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico: Non-Alcoholic Steatohepatitis Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico Non-Alcoholic Steatohepatitis Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Non-Alcoholic Steatohepatitis Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 15. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 16. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 17. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 18. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 19. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 20. Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 21. France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 22. France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 23. France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 24. UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 25. UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 26. UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 27. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 28. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 29. Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 30. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 31. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 32. Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 33. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)
Table 34. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 35. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 36. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 37. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 38. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 39. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 40. China: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 41. China: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 42. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 43. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 44. Japan: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 45. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 46. India: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 47. India: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 48. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 49. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 50. Australia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 51. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 52. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 53. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 54. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Product – Revenue and Forecast to 2028 (USD Million)
Table 55. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, By Application – Revenue and Forecast to 2028 (USD Million)
Table 56. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (USD Million)
Table 57. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Product (US$ Million)
Table 58. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Application (US$ Million)
Table 59. Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)
Table 60. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 61. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 62. UAE: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)
Table 63. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 64. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 65. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel– Revenue and Forecast to 2028 (US$ Million)
Table 66. South Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 67. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 68. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 69. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Product (US$ Million)
Table 70. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 71. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)
Table 72. South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)
Table 73. South and Central America: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 74. South and Central America: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)
Table 75. Brazil: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)
Table 76. Brazil: Non-Alcoholic Steatohepatitis Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 77. Brazil: Non-Alcoholic Steatohepatitis Market, by Sales Channel– Revenue and Forecast to 2028 (USD Million)
Table 78. Argentina: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)
Table 79. Argentina: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)
Table 80. Argentina: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)
Table 81. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Product – Revenue and Forecast to 2028 (USD Million)
Table 82. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Application– Revenue and Forecast to 2028 (USD Million)
Table 83. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market , by Sales Channel– Revenue and Forecast to 2028 (USD Million)
Table 84. Organic Developments Done By Companies
Table 85. Inorganic Developments Done By Companies
Table 86. Glossary of Terms
LIST OF FIGURES
Figure 1. Non-Alcoholic Steatohepatitis Market Segmentation
Figure 2. Non-Alcoholic Steatohepatitis Market, By Region
Figure 3. Global Non-Alcoholic Steatohepatitis Market Overview
Figure 4. Treatment Segment Held Largest Share of Application Segment in Non-Alcoholic Steatohepatitis Market
Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Non-Alcoholic Steatohepatitis Market, by Geography (US$ Million)
Figure 7. Global Non-Alcoholic Steatohepatitis Market - Leading Country Markets (US$ Million)
Figure 8. Global Non-Alcoholic Steatohepatitis Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East And Africa: PEST Analysis
Figure 13. South And Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Non-Alcoholic Steatohepatitis (NASH) Market Impact Analysis of Drivers and Restraints
Figure 16. Global Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis – 2020- 2028
Figure 17. Global Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 18. Global Non-Alcoholic Steatohepatitis Market – Market Potential Analysis, By Region
Figure 19. Market Positioning Analysis of Key Players in Global Non-Alcoholic Steatohepatitis Market
Figure 20. Global Non-Alcoholic Steatohepatitis Market – Comparative Company Analysis
Figure 21. Global Non-Alcoholic Steatohepatitis Market – Growth Strategy Analysis
Figure 22. Product Market Analysis and Forecast 2021 and 2028 (%)
Figure 23. Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)
Figure 24. Ocaliva Revenue and Forecast to 2028 (US$ Mn)
Figure 25. Elafibranor Revenue and Forecast to 2028 (US$ Mn)
Figure 26. Selonsertib Revenue and Forecast to 2028 (US$ Mn)
Figure 27. Others Revenue and Forecast to 2028 (US$ Mn)
Figure 28. Application Market Analysis and Forecast 2021 and 2028 (%)
Figure 29. Treatment Market Revenue and Forecast to 2028 (US$ Mn)
Figure 30. Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)
Figure 31. Sales Channel Market Analysis and Forecast 2021 and 2028 (%)
Figure 32. Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
Figure 33. Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
Figure 34. Online Provider Market Revenue and Forecast to 2028 (US$ Mn)
Figure 35. North America: Non-Alcoholic Steatohepatitis Market, by Key Country – Revenue (2021) (US$ Million)
Figure 36. North America Non-Alcoholic Steatohepatitis Market Revenue and Forecast to 2028 (US$ Million)
Figure 37. North America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)
Figure 38. US: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Canada: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Mexico: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (US$ Million)
Figure 42. Europe: Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
Figure 43. Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)
Figure 44. Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)
Figure 50. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (USD Million)
Figure 51. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (USD Million)
Figure 52. Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)
Figure 53. China: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
Figure 54. Japan: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
Figure 55. India: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028(USD Million)
Figure 56. Australia: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
Figure 57. South Korea: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
Figure 58. Rest of Asia Pacific: Non-Alcoholic Steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (USD Million)
Figure 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
Figure 61. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028, by Country (%)
Figure 62. UAE: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
Figure 63. Saudi Arabia: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
Figure 64. South Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
Figure 65. Rest of Middle East & Africa: Non-Alcoholic Steatohepatitis (NASH) Market Revenue and Forecast to 2028 (US$ Million)
Figure 66. South and Central America: Non-Alcoholic Steatohepatitis Market, by Key Country – Revenue (2021) (USD Million)
Figure 67. South and Central America Non-Alcoholic Steatohepatitis Market Revenue and Forecast to 2028 (USD Million)
Figure 68. South and Central America: Non-Alcoholic Steatohepatitis Market, by Country, 2021 & 2028 (%)
Figure 69. Brazil: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
Figure 70. Argentina: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
Figure 71. Rest of South and Central America: Non-Alcoholic Steatohepatitis Market – Revenue and Forecast to 2028 (USD Million)
Figure 72. Impact of COVID-19 Pandemic in North American Country Markets
Figure 73. Impact of COVID-19 Pandemic in European Country Markets
Figure 74. Impact of COVID-19 Pandemic in Asia Pacific Countries
Figure 75. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 76. Impact of COVID-19 Pandemic in South and Central America Country Markets
Figure 77. Growth Strategies in the Non-Alcoholic Steatohepatitis Market
- Genfit SA
- One Way Liver, S.L.
- BioPredictive S.A.S
- Cadila Pharmaceuticals Ltd.
- Prometheus Laboratories
- Siemens Healthineers AG
- Intercept Pharmaceuticals, Inc.
- Novartis AG
- Galmed Pharmaceuticals
- Laboratory Corporation of America Holdings
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Non-Alcoholic Steatohepatitis (NASH) Market
Apr 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)